Detect and Monitor ctDNA in NSCLC to Inform Treatment Strategy
![icon_1_pub Test](https://www.natera.com/wp-content/uploads/2022/04/icon_1_pub.png)
Identify High Risk Patients
Test for presence of MRD after definitive therapy to assess prognosis1-2
53x
Higher risk of recurrence
for ctDNA positive patients1
![icon_3_support Know](https://www.natera.com/wp-content/uploads/2022/04/icon_3_support.png)
Detect Recurrence Earlier
Detect recurrence before
radiographic imaging1-2
5-6 months
Median lead time over
radiographic recurrence1-2
![icon_3_support Decide](https://www.natera.com/wp-content/uploads/2022/04/icon_3_support.png)
Monitor Immunotherapy
Treatment Response
Track early changes in ctDNA levels to predict outcomes3
96% lower
Risk of death for patients who cleared their ctDNA by week 9 compared to patients with increasing ctDNA3
Evaluate Response to ICI Treatment in NSCLC
ICI (immune checkpoint inhibitors) are FDA-approved with guideline recommendations across all treatment settings in lung cancer (neoadjuvant, adjuvant, locally advanced, metastatic).4
Signatera™ was evaluated in the EMPower Lung-1 trial, a prospective study in patients with advanced or metastatic NSCLC randomized to ICI vs chemotherapy for 1L treatment3
- Rising ctDNA by week 3 or lack of ctDNA clearance by week 9 identified patients experiencing inferior clinical outcomes
- ctDNA deep decrease (>90%) and clearance were associated with significantly improved OS
- Composite ctDNA & RECIST assessment may improve prediction of OS benefit from IO
Inform Your Lung Cancer Treatment Approach With Signatera™
Monitoring circulating tumor DNA (ctDNA) with Signatera™ across the treatment journey can answer important clinical questions and inform treatment decisions.
![signatera-lung-inform-your-treatment-updated-3 alt text](https://www.natera.com/wp-content/uploads/2022/09/signatera-lung-inform-your-treatment-updated-3.png)
Discover the Data in Lung Cancer
-
Immunotherapy Response Monitoring
- Rising ctDNA by week 3 or lack of ctDNA clearance by week 9 identified patients experiencing inferior clinical outcomes
- Composite ctDNA & RECIST assessment may improve prediction of OS benefit from IO3
-
Adjuvant (resectable) / Surveillance
-
Adjuvant (unresectable) / Surveillance
![ONC-Altera-Altera-report](https://www.natera.com/wp-content/uploads/2022/08/ONC-Altera-Altera-report.png)
Do More With Less Tissue
One tumor sample – two tests
Reassure Your Patients Living With Lung Cancer
After JoAnn was diagnosed with lung cancer, Signatera™ detected a rise in her ctDNA levels, alerting her oncologist to a progression that was not scannable.
Watch JoAnn’s story to learn how she and her oncologist added Signatera™ testing to their toolbelt to help closely monitor her cancer.
“I want to know. The more you know, the better off you are.” – JoAnn, living with lung cancer
Lung Cancer Resources
![Benefits-of-ctDNA](https://www.natera.com/wp-content/uploads/2023/09/Benefits-of-ctDNA.png)
The benefits of using ctDNA over traditional scans to assess responses to ICI
Dr. Natalie Vokes shares thoughts on how ctDNA can be used in addition to scans in NSCLC
![SGN_WEB_Lung_Clinician_Resource_Image_406x222_20240412_NAT-1116 Signatera IO Monitoring in Lung Cancer](https://www.natera.com/wp-content/uploads/2024/04/SGN_WEB_Lung_Clinician_Resource_Image_406x222_20240412_NAT-1116.jpg)
Signatera™ IO Monitoring in Lung Cancer
Learn about Signatera™ for risk-stratification, surveillance, and immunotherapy response monitoring
![ONC_IO_Web_Image1_20230920](https://www.natera.com/wp-content/uploads/2023/09/ONC_IO_Web_Image1_20230920.jpg)
Patient Case Study
Read how Signatera™ detected a rise in ctDNA levels during immunotherapy, informing the decision to pivot to a combination therapy approach.
Ready to try Signatera™ for your lung cancer patients?
*OS = Overall Survival
References
1Martin TK, Dinerman A, et al. Early Real-World Experience Monitoring Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer. J Thorac Cardiovasc Surg. 2024. doi: 10.1016/j.jtcvs.2024.01.017.
2Lebow E, et al. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy. Front. Oncol. 2023,13:1253629.
3Vokes N, Gandara D, et al. Circulating Tumor DNA (ctDNA) Dynamics and Survival Outcomes in Patients with Advanced NSCLC and High (greater than 50%) PD-L1 Expression, Randomized to Cemiplimab vs Chemotherapy. Presented at ASCO Annual Meeting, Chicago, IL, June 2023.
4NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Non-Small Cell Lung Cancer V1.2024.